Oncology

Selpercatinib is the first therapy approved specifically for cancer patients with rearranged during transfection (RET) gene alterations.

In outpatient breast cancer clinics, oral chemotherapies are becoming more common for various malignancies, but hematologic and non-hematologic toxicities can cause challenges for patients.

Steve D'Amato, BScPharm, CEO of New England Cancer Specialists, discusses how the COVID-19 pandemic has affected cancer care.

Oral oncolytics has become increasingly common as treatment for patients with cancer over the past several years.

According to the investigators, the cells are called ductal macrophages and function by consuming dying milk-producing cells, which need to be cleared away after milk production stops.

The objective of the study was to develop an education program that increased confidence and knowledge of pharmacists managing CDK4/6 inhibitors.

Christian G. Downs, JD, MHA, executive director of the Association of Community Cancer Centers, discusses cancer politics and policy today.

Non-small cell lung cancer is a the most common type of lung cancer with up to 90% of all lung carcinomas falling into the non-small cell category.

"Approximately 40% of melanomas are considered to be ‘cold,’ meaning that they lack sufficient infiltration of immune cells within the tumor."

In a new study, researchers analyzed data on cancer survivors' experiences with financial toxicity and found that survivors have unmet needs in its management.

The drug is co-formulated with recombinant human hyaluronidase PH20 and will be available as soon as the week of May 11.

In the oral chemotherapy setting, pharmacist care exceeded patients’ expectations and helped manage and avoid adverse events (AEs).

Researchers have developed a new way to map the molecules on tumor cells that flag their presence to the immune system.

Mathematicians at Cornell University are using game theory to model how cancer treatment may be administered more sparingly with maximized effect.

The findings are part of the I-SPY clinical trial and were presented at the American Association for Cancer Research virtual annual meeting.

Although lifesaving drugs became available around 1998 to treat hepatitis C, they were expensive, which limited access for some patients.

The objective of the study was to examine whether positive treatment effects in cancer randomized clinical trials apply to specific demographic or insurance subgroups.

A recent study presented a risk prediction model that effectively combined genetic and clinical factors with circulating biomarkers to identify people with a higher than normal risk of pancreatic cancer.

New research has discovered new elements to immunotherapy drugs that target programmed death-ligand 1 on the surface of cancer cells.

There are few effective treatment options for patients with HER2-positive breast cancer who have received 2 or more previous therapies for advanced disease, according to the study authors.

A randomized clinical trial offers strong evidence that a combination of 2 targeted melanoma drugs when given continuously keeps cancer from growing or spreading longer compared with intermittent treatment.

The results of the ongoing trial were presented at the 2020 American Association for Cancer Research Virtual Annual Meeting I.

Rucaparib is FDA approved in patients with a BRCA mutation and who have received 2 more prior lines of previous chemotherapy.

Previously, the only women with ovarian cancer eligible to be treated with PARP inhibitors as monotherapy in the maintenance setting were those with a BRCA mutation.

According to new research, biomarkers that signal whether a patient's cancer treatment may be harming their heart have been identified.

Researchers have discovered a natural protective mechanism that leads to the programmed death of potentially diseased cancer cells.

In a lecture at the virtual Community Oncology Conference 2020, Christine Roussel discussed some clinical considerations for the use of medical cannabis in patients with cancer.

Research confirms earlier studies that found talazoparib improved patient-reported quality-of-life measures and had a tolerable safety profile.